LBT granted key European patent

LBT Innovations (formerly LabTech Systems), an Australian developer of clinical and diagnostic technology based in Adelaide, has been granted its patent by the European Patent Office for the agar plate streaking technology, which is at the core of the company's MicroStreak system.

LBT Innovations (formerly LabTech Systems), an Australian developer of clinical and diagnostic technology based in Adelaide, has been granted its patent by the European Patent Office for the agar plate streaking technology, which is at the core of the company's MicroStreak system.

The European patent secures LBT's intellectual property in 27 countries and adds to the full grant of the patent in Australia.

"This European patent grant is an important step forward for LBT as the technology gains traction in laboratories in Europe and around the world," said LBT Innovations ceo Lusia Guthrie.

The European patent covers the methods and unique design of the agar plate streaker, which was licensed to French diagnostics company bioMerieux in 2007.

The technology was launched last year across global pathology markets and is marketed by bioMerieux as PREVI Isola.

A number of these systems have now been installed in laboratories in the US, Europe (in France, Germany, the Netherlands, Sweden, Switzerland, Belgium and the UK) and China.

The European Patent Office granted the patent to Medvet Science, which has licensed exclusive worldwide rights to the technology to LBT Innovations. It will take effect from 17 February.

The technology inventors, John Glasson and Lachlan Smith, worked at the Institute of Medical and Veterinary Science (IMVS) in Adelaide when the patent was filed.




Companies